(Q38116754)

29 August 2017

0 references

Overview of the latest treatments for castration-resistant prostate cancer (English)

1 reference

29 August 2017

1 reference

2

Fred Saad

1 reference

29 August 2017

Mohamed Bishr

1

1 reference

PubMed ID

23797341

29 August 2017

language of work or name

English

0 references

publication date

25 June 2013

1 reference

29 August 2017

Nature Reviews Urology

1 reference

29 August 2017

10

1 reference

29 August 2017

9

1 reference

29 August 2017

522-528

1 reference

https://scigraph.springernature.com/pub.10.1038/nrurol.2013.137

29 August 2017

0 references

cites work

The androgen axis in recurrent prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.137

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.137

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.137

Mechanisms of androgen-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.137

Common structural and epigenetic changes in the genome of castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.137

Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.137

Intragenic rearrangement and altered RNA splicing of the androgen receptor in a cell-based model of prostate cancer progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.137

Activation of the androgen receptor N-terminal domain by interleukin-6 via MAPK and STAT3 signal transduction pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.137

Src kinase potentiates androgen receptor transactivation function and invasion of androgen-independent prostate cancer C4-2 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.137

The influence of androgen deprivation therapy on dihydrotestosterone levels in the prostatic tissue of patients with prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.137

Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.137

Antiandrogen monotherapy: recommendations for the treatment of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.137

Estrogens in the Treatment of Prostate Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.137

Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.137

Antiandrogen withdrawal in castrate-refractory prostate cancer: a Southwest Oncology Group trial (SWOG 9426)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.137

Low-dose diethylstilbestrol for the treatment of advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.137

Potential mechanism for the effects of dexamethasone on growth of androgen-independent prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.137

Glucocorticoids suppress tumor angiogenesis and in vivo growth of prostate cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.137

Novel steroidal inhibitors of human cytochrome P45017 alpha (17 alpha-hydroxylase-C17,20-lyase): potential agents for the treatment of prostatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.137

Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.137

Abiraterone in metastatic prostate cancer without previous chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.137

Development of a second-generation antiandrogen for treatment of advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.137

Increased survival with enzalutamide in prostate cancer after chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.137

The cancer vaccine roller coaster

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.137

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.137

Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.137

Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.137

CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.137

A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.137

Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.137

First- and second-line chemotherapy with docetaxel or mitoxantrone in patients with hormone-refractory prostate cancer: does sequence matter?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.137

Survival and PSA response of patients in the TAX 327 study who crossed over to receive docetaxel after mitoxantrone or vice versa

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.137

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.137

Docetaxel reintroduction in patients with metastatic castration-resistant docetaxel-sensitive prostate cancer: a retrospective multicentre study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.137

Phase II study of docetaxel re-treatment in docetaxel-pretreated castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.137

The interval from the last cycle of docetaxel-based chemotherapy to progression is associated with the efficacy of subsequent docetaxel in patients with prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.137

The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.137

Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.137

The relationship between daily calcium intake and bone mineral density in men with prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.137

Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.137

The antiosteoporotic efficacy of intravenous pamidronate in men with prostate carcinoma receiving combined androgen blockade: a double blind, randomized, placebo-controlled crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.137

Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.137

Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.137

Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.137

A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.137

Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.137

Safety of intravenous and oral bisphosphonates and compliance with dosing regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.137

Osteoclast differentiation and activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.137

Denosumab in men receiving androgen-deprivation therapy for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.137

Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.137

Emerging therapies to prevent skeletal morbidity in men with prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.137

Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.137

Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.137

Systemic metabolic radiopharmaceutical therapy in the treatment of metastatic bone pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.137

Expanding treatment options for metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.137

Heat shock protein 27 increases after androgen ablation and plays a cytoprotective role in hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.137

Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.137

Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.137

Response to second-line chemotherapy in patients with hormone refractory prostate cancer receiving two sequences of mitoxantrone and taxanes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.137

Rational indication for docetaxel rechallenge in metastatic castration-resistant prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.137

Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.137

Safety and efficacy of cabazitaxel in the docetaxel-treated patients with hormone-refractory prostate cancer.

31 March 2020

1 reference

12 December 2020

Efficacy of low-dose dexamethasone in castration-refractory prostate cancer

1 reference

12 December 2020

Estrogens in the treatment of prostate cancer

1 reference

12 December 2020

Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer

1 reference

12 December 2020

Functional characterization of mutant androgen receptors from androgen-independent prostate cancer.

1 reference

12 December 2020

Current management of castrate-resistant prostate cancer.

1 reference

12 December 2020

Docetaxel in the treatment of metastatic castration-resistant prostate cancer (mCRPC): an observational study in a single institution.

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRUROL.2013.137

1 reference

PubMed ID

23797341

Dimensions Publication ID

29 August 2017

0 references

1 reference

PubMed ID

23797341